Research programme: PDGF - Seattle Life Sciences

Drug Profile

Research programme: PDGF - Seattle Life Sciences

Alternative Names: PDGF-C; PDGF-D; Platelet derived growth factor; Zvegf4

Latest Information Update: 14 Sep 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ZymoGenetics
  • Developer Seattle Life Sciences
  • Class Antineoplastics; Antiulcers; Growth factors; Immunotherapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Unspecified

Most Recent Events

  • 14 Sep 2010 Discontinued - Preclinical for Undefined indication in USA (Parenteral)
  • 05 May 2009 Preclinical trials in Undefined indication in USA (Parenteral)
  • 05 Aug 2002 Preclinical trials in Fracture in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top